For the first time in China! Reimsima, a South Korean bio generic drug, enters the Chinese market

Source: nai500 May 24, 2017, saierqun, a South Korean biotechnology company, announced that it had received the clinical trial license from China food and drug administration Remsima is a bio generic drug for the treatment of rheumatoid arthritis and ulcerative colitis This is the first time that the Chinese government has approved the clinical trials of biosimilars by foreign companies At the same time, in order to promote the sales of remsima in China, celgroup is planning to establish a factory in China To enter China with relatively high barriers to entry, clinical trials usually take a long time to be approved In January 2014, seergroup submitted the application for clinical trial of remsima to China food and drug administration, which was finally approved after two years of quality evaluation Remsima is a bio generic of REMICADE of Janssen Pharmaceutical Last year, the global sales volume of imicade reached 9.7 billion US dollars, of which the sales volume in China was about 10 million US dollars, which has set a new sales record.